Abstract:Background: Inherited medullary thyroid carcinoma (MTC) is primarily caused by RET mutations that are commonly localized in exons 5, 8, 10, 11, and 13-16. In this study, we report pedigrees for individuals with MTC that harbor a germline S409Y variant within exon 6 of the RET proto-oncogene. Methods: Targeted sequencing was used to diagnose four apparently sporadic MTC index cases carrying the germline RET S409Y (c.1226 C>A) variant. Subsequently, 27 relatives of these individuals underwent clinical and genetic assessments and/or thyroid surgery. Furthermore, in silico analyses and in vitro assays were performed to predict or verify the potential oncogenic activity of the S409Y variant. Results: Overall, 15 of 31 participants were found to carry the RET S409Y variant. Of these, 6 presented with isolated MTC (mean age 50.2 years; range 41-75 years), of which 3 presented with neck lymph node metastases and 2 presented with distant liver or lung metastases. Among the remaining 9 carriers, 3 (mean age 56 years; range 41-76 years) had elevated serum calcium-stimulated calcitonin (sCtn) or concurrent marginally elevated serum calcitonin (Ctn) levels, whereas the other 6 (mean age 37.5 years; range 14-52 years) exhibited typical Ctn/sCtn levels (p < 0.05). None of the 15 carriers in these 4 families presented clinical evidence of pheochromocytoma, hyperparathyroidism, or Hirschsprung's disease. In silico analyses revealed that S409Y was a "possibly damaging" mutation that could affect the RET protein inter-domain interface. An in vitro assay revealed that the phosphorylation level of RET tyrosine 905 was relatively higher in the RET S409Y mutant than in wild-type (WT) RET. Moreover, transfection of HEK 293 cells with S409Y enhanced the phosphorylation activity of AKT, ERK pathways, and it increased cell proliferation compared with WT RET, but to a lesser degree than that for the RET C618Y and C634Y mutations. Conclusions: This study demonstrates that the novel germline RET S409Y variant is likely pathogenic and is associated with lower penetrance of MTC than that for the C618Y and C634Y mutations. Individuals with S409Y should be managed using a personalized approach, and additionally, "at-risk" family members should be evaluated. Additional studies are needed to elucidate the correlation between the S409Y mutation and multiple endocrine neoplasia type 2-specific tumors.

Ret: A Receptor Tyrosine Kinase and Its Mutation and Human Diseases.

RET S409Y Germline Mutation and Associated Medullary Thyroid Carcinoma.

RET Receptor Tyrosine Kinase: Role in Neurodegeneration, Obesity, and Cancer

Neurotrophic factor receptor RET: structure, cell biology, and inherited diseases

Structure and Physiology of the RET Receptor Tyrosine Kinase.

An integrative pan cancer analysis of RET aberrations and their potential clinical implications

Identifying novel oncogenic <i>RET</i> mutations and characterising their sensitivity to RET-specific inhibitors

The importance of the RET gene in thyroid cancer and therapeutic implications

Precious Gene: The Application of RET-Altered Inhibitors

Screening of RET Gene Mutations in Chinese Patients with Medullary Thyroid Carcinoma and Their Relatives

Cellular Mechanisms of RET Receptor Dysfunction in Multiple Endocrine Neoplasia 2

A comprehensive overview of RET fusion lung caner’s characters, diagnosis and treatment

Pathogenesis Of Ron Receptor Tyrosine Kinase In Cancer Cells: Activation Mechanism, Functional Crosstalk, And Signaling Addiction

Receptor tyrosine kinase RON and tumor

Targeting RET mutation in medullary thyroid cancer

Mutation of the RET Proto-Oncogene in Hirschsprung^s Disease

REThinking the role of the RET oncogene in breast cancer

Precision therapy for RET-altered cancers with RET inhibitors

[Gene Rearrangement Analysis of Papillary Thyroid Carcinoma].

Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations

A Novel Germline Deletion of P.c630 in RET Causes MTC and Promotes Cell Proliferation and Sensitivity to Pralsetinib.